IP Library Granted Patent US 10,898,442
Granted Patent B2
US 10,898,442 · App. 15/564,635 · Granted Jan 26, 2021

Microencapsulates containing stabilised lipid, and methods for the production thereof

Inventor: Sinead Bleiel (Dublin, IE)
Assignee: Anabio Technologies Limited
A61K9/5036A23L27/72A23L29/275A23L33/115A23L33/12A23P10/30A23P10/35A23P30/25A61K9/1075A61K35/612A61K47/44A23V2002/00A23V2250/1862A23V2250/1868A23V2250/511A23V2250/5114A23V2250/616A23V2250/628
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,442
App. No.
15/564,635
Granted
Jan 26, 2021
Kind
B2
Abstract

The invention provides a gelated mono-nuclear microencapsulate comprising a lipid emulsion core encapsulated within a gastro-resistant, ileal sensitive, polymerized chitosan membrane shell, wherein the lipid emulsion core comprises denatured or hydrolysed protein and carbohydrate. In one embodiment of the invention, the emulsion is a micro-emulsion, and typically comprises a surfactant and a co-surfactant or at least two carbohydrates, for example sucrose and a maltodextrin. In one embodiment of the invention, the lipid is a marine derived lipid such as fish oil, krill oil, or nutraceutical fatty acids. In other embodiment, the lipid is a fatty acid such as DHA or ARA, or a lipid derived from seeds, nuts or eggs.

Claims (19)

1. A gelated mono-nuclear microencapsulate, formed by extrusion of microdroplets into an acidic gelling bath for immediate curing therein, comprising a lipid microemulsion core encapsulated within a gastro-resistant and ileal sensitive polymerized chitosan membrane shell, wherein the lipid microemulsion core includes a denatured or hydrolysed protein, a carbohydrate, and a lipid in a microemulsion that is a self microemulsifying drug delivery system containing a surfactant and a co-surfactant; and the shell is impermeable to air.

2. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the lipid is selected from a marine-derived lipid; a lipid derived from nuts, seeds, or eggs; a fatty acid; and a triglyceride.

3. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the lipid is a marine derived oil selected from fish oil, hill oil, and algal oil.

4. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the lipid is a fatty acid selected from docosahexaenoic acid (DHA) and arachidonic acid (ARA).

5. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the carbohydrate is a polysaccharide.

6. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the carbohydrate is a glucose-containing polysaccharide, optionally selected from maltodextrin, sucrose, and maltose.

7. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the carbohydrate is a disaccharide.

8. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the carbohydrate has a dextrose equivalence of 16-20.

9. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the shell further includes a co-surfactant that, optionally, is lecithin.

10. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the shell further includes a denatured or hydrolysed protein.

11. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the denatured or hydrolysed protein of the lipid microemulsion core comprises a dairy protein, a vegetable protein, or both.

12. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which:

the lipid microemulsion core comprises 5.5 to 86.0% total solids (w/v); and/or

the lipid microemulsion core comprises 5.5 to 15% denatured or hydrolysed protein (w/v); and/or

the lipid microemulsion core comprises 2.0 to 8.5% carbohydrate (w/v).

13. A gelated mono-nuclear microencapsulate as claimed in claim 1 in which the microencapsulate is dried.

14. A composition suitable for oral administration to a mammal, the composition comprising a multiplicity of microencapsulates according to claim 1 .

15. A composition suitable for oral administration to a mammal, the composition comprising a multiplicity of microencapsulates according to claim 1 , wherein the composition is selected from a food product, a beverage, a food ingredient, an animal feed ingredient, a nutritional supplement, an infant formula, an animal feed supplement, and an oral dosage pharmaceutical.

16. A composition suitable for oral administration to a mammal, the composition comprising a multiplicity of microencapsulates according to claim 1 , wherein the composition is an infant formula and the lipid in each of the microencapsulates is selected from DHA and ARA.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2022
From: ZANTEBIO LIMITED
To: TEAGASC - THE AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY
Reel/Frame 062193/0512 →
CHANGE OF NAME Recorded Nov 28, 2022
From: NUABIOME LIMITED
To: ZANTEBIO LIMITED
Reel/Frame 061892/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: ANABIO TECHNOLOGIES LIMITED
To: NUABIOME LIMITED
Reel/Frame 057410/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: BLEIEL, SINEAD
To: ANABIO TECHNOLOGIES LIMITED
Reel/Frame 044559/0001 →
Priority Claims (1)
GB 1509606.8 · Jun 3, 2015 · national
Continuity (1)
Related Publication 20180071224A1 · Mar 15, 2018